Trial Profile
ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Leuprorelin (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms AASUR
- 08 Feb 2022 Planned End Date changed from 1 May 2022 to 1 May 2023.
- 08 Feb 2022 Planned primary completion date changed from 1 May 2022 to 1 May 2023.
- 12 Jan 2022 Results (n=303) assessing dermatologic adverse events frequency and time to onset and characterize clinicopathologic features in a large cohort of PCa patients treated with apalutamide and recommend management strategies based on multidisciplinary (oncologist-dermatologist) experience from 7 clinical trials (NCT03009981, NCT01171898, NCT03141671, NCT03436654, NCT02903368, NCT02772588 and NCT02106507) and off-trial, published in the Journal of Urology.